Last reviewed · How we verify
Nicotine gum (C)
Nicotine gum delivers nicotine through the oral mucosa to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation.
Nicotine gum delivers nicotine through the oral mucosa to bind nicotinic acetylcholine receptors in the brain, reducing cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation aid, Reduction of cigarette consumption.
At a glance
| Generic name | Nicotine gum (C) |
|---|---|
| Sponsor | 22nd Century Group, Inc. |
| Drug class | Nicotinic acetylcholine receptor agonist |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Addiction Medicine / Smoking Cessation |
| Phase | FDA-approved |
Mechanism of action
Nicotine acts as an agonist at nicotinic acetylcholine receptors, particularly in the mesolimbic dopamine pathway, which mediates reward and addiction. By providing exogenous nicotine without the harmful combustion byproducts of cigarettes, nicotine replacement therapy reduces the severity of withdrawal symptoms and cravings, facilitating abstinence from tobacco smoking. The gum formulation allows for flexible, on-demand dosing as users gradually reduce their nicotine dependence.
Approved indications
- Smoking cessation aid
- Reduction of cigarette smoking
Common side effects
- Mouth irritation
- Hiccups
- Dyspepsia
- Jaw soreness
- Nausea
- Headache
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics (PHASE4)
- C-Raven, a Virtual Tobacco Cessation Intervention in the Community (PHASE4)
- Abuse Liability for Eight Electronic Nicotine Products (NA)
- Abuse Liability for Five Modern Oral Nicotine Products (NA)
- Modern Nicotine Oral Product Abuse Liability (NA)
- Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community (PHASE4)
- Changes in Oral Health in Tobacco Cigarettes Smokers After Switching to Combustion-Free Nicotine Delivery Systems (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotine gum (C) CI brief — competitive landscape report
- Nicotine gum (C) updates RSS · CI watch RSS
- 22nd Century Group, Inc. portfolio CI